# Viking starts oral VK2735 Phase 3 program, the SUNRISE trials

Canonical page: https://technooptimist.io/stories/viking-starts-oral-vk2735-phase-3-program-the-sunrise-trials-0f1b5d38
Date: 14 Oct 2026
About: [Viking Therapeutics](https://technooptimist.io/companies/viking-therapeutics.md) · [VK2735](https://technooptimist.io/biotech/vk2735.md)
Original source: https://ir.vikingtherapeutics.com/2026-10-14-Viking-Therapeutics-Announces-Initiation-of-VK2735-Oral-Phase-3-Clinical-Program-in-Patients-with-Obesity

Viking announced the start of a Phase 3 program for oral VK2735, its daily pill version of the GLP-1/GIP dual agonist, under the name SUNRISE. Two randomized, double-blind, placebo-controlled trials will test once-daily oral doses for 68 weeks, one in adults with obesity or overweight and one in adults with type 2 diabetes. The release gives no first-enrollment date.

## Key facts

- SUNRISE-1 covers adults with obesity or overweight without type 2 diabetes who have at least one weight-related condition; SUNRISE-2 covers adults with type 2 diabetes who are obese or overweight.
- Each trial targets 560 adults.
- Participants are randomized to 27.5 mg, 35 mg or 55 mg of oral VK2735 once daily, or placebo.
- The primary endpoint is percent change in body weight from baseline versus placebo after 68 weeks.
- The release does not say how the three doses were chosen, and it gives no timing for enrollment or data.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.